← ANALYST RATINGS · TIPRANKS
Cullinan Management (CGEM): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $35.62, the highest $47.00, the lowest $27.00. The average is +175.5% from the last price of $12.93.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $14.00 → $13.00−7.1% | Hold | +0.5% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $13.50 → $12.50−7.4% | Hold | −3.3% | Upgrade | 17.10.26on TipRanks 07:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $13.50 → $13.00−3.7% | Hold | +0.5% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $13.50 → $13.00−3.7% | Hold | +0.5% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $14.00 → $13.50−3.6% | Hold | +4.4% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.50 → $13.00−3.7% | Hold | +0.5% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $42.00 | Buy | +224.8% | Reiterated | 07.10.26on TipRanks 10:25 | −3.6%next day −0.7% · 5 days −11.8% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $33.00 | Buy | +155.2% | Reiterated | 06.10.26on TipRanks Oct 7 05:25 | +0.8%next day −3.6% · 5 days −13.1% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 02.10.26on TipRanks 09:55 | +6.0%next day +2.7% · 5 days −1.0% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $35.00 | Buy | +170.7% | Reiterated | 02.10.26on TipRanks 07:07 | +6.0%next day +2.7% · 5 days −1.0% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $40.00 | Buy | +209.4% | Reiterated | 01.10.26on TipRanks Oct 2 06:16 | −5.5%next day +6.0% · 5 days +5.1% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 24.09.26on TipRanks 13:20 | −8.4%next day −4.6% · 5 days −5.5% | ↗ |
| Unknown Analyst | Leerink Partners | $38.00 → $39.00+2.6% | Buy | +201.6% | Reiterated | 16.09.26on TipRanks Sep 22 21:11 | +0.9%next day +2.4% · 5 days −20.3% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $30.00 | Buy | +132.0% | Reiterated | 15.09.26on TipRanks 07:25 | +1.1%next day +0.9% · 5 days +3.1% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $36.00 | Buy | +178.4% | Reiterated | 14.09.26on TipRanks 05:55 | −0.5%next day +1.1% · 5 days +2.7% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $24.00 → $27.00+12.5% | Buy | +108.8% | Reiterated | 17.08.26on TipRanks 08:55 | +1.7%next day +1.9% · 5 days +7.2% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $46.00 → $47.00+2.2% | Buy | +263.5% | Assigned | 14.08.26on TipRanks Aug 13 09:30 | −0.5%next day +3.8% · 5 days +10.8% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $28.00 | Buy | +116.6% | Reiterated | 13.08.26on TipRanks 11:35 | −0.5%next day +3.8% · 5 days +10.8% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $30.00 | Buy | +132.0% | Reiterated | 10.03.26on TipRanks Mar 11 06:55 | −2.5%next day −3.9% · 5 days −8.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Cullinan Management
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $35.70 at a price of $15.35 (+132.6%); now: $35.70 at $12.93 (+176.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 24 | 22 | 14 | 10 | 11 |
| Buy | 4 | 5 | 5 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.84 (from $-1.04 to $-0.71). Last quarter: $-0.81.
Best top-analyst consensus in the sector · Healthcare
About Cullinan Management
- CEO: Nadim Ahmed
- Employees: 109
- One Main Street, Cambridge, MA, 02142, US
- cullinantherapeutics.com
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 37 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗